AbbVie fully ditches I-Mab’s CD47 drug after initial 2022 pullback from $1B+ bet

AbbVie will end the last parts of its CD47 agreement with I-Mab, the Maryland and Shanghai biotech disclosed in a Friday SEC filing.

The Chicago-area drugmaker will return the global rights to develop and commercialize certain CD47 antibodies and products that were set up under the…
Click here to view original post